Continuous subcutaneous insulin infusion and type 2 diabetes

Seminars of diabetes - Vol.21 N.2  April-June 2005
I. Conget Donlo¹, S. Rueda²

 Author Affiliations

Abstract

Insulin pump therapy or continuous subcutaneous insulin infusion (CSII) has become an increasingly popular mode of insulin therapy for patients with type 1 diabetes mellitus. It is now considered as an alternative to conventional multiple doses insulin therapy after the failure of the last one. Although the benefits of therapy with CSII, such as less glycaemic variability and a more flexible lifestyle, should be similar for patients with type 1 and type 2 diabetes, data on the use of CSII in patients with type 2 diabetes are scarce and limited. In this article, we review the available information concerning the use of CSII, as well as the clinical situations where it may be considered as a treatment in the future, in subjects with type 2 diabetes mellitus.

Correspondence

Correspondencia: Dr. Ignacio Conget. Médico Consultor. Endocrinologia
y Diabetes. Hospital Clínic i Universitari de Barcelona,
IDIBAPS (Institut d’Investigacions Biomèdiques August
Pi i Sunyer). Villarroel 170, 08036 Barcelona.
E-mail: iconget@clinic.ub.es.

Keywords

type 2 diabetes continuous subcutaneous insulin infusion

Document

PDF Document (Original in spanish)

Seminary

Therapy with continuous subcutaneous insulin (II)

‹ Back